Product description

Accelerating orphan drug development from candidate selection to commercial manufacture and supply.

With over 300 million people worldwide living with identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of great interest in the pharmaceutical industry.

Despite improvements in regulatory support and commercial rewards for developing orphan drugs, difficulties remain for drug developers in bringing these medicines to market quickly; including limited R&D budgets, alongside an ever-evolving regulatory framework, challenging product development and clinical recruitment.

- Integrated capabilities and expertise- Pre-formulation and API characterisation
- Formulation and process development
- First-in-human clinical testing and acceleration into POC trials
- Bespoke clinical manufacturing and supply (Phase I-III) of drug products into patient trials
- Rapid scale-up and commercial manufacturing of low-volume products
Read more

Specifications

Categories Contract Services - Pre Clinical Trials, Clinical Trials Stages 1-4, CRO, Clinical DataClinical Research (Field); Contract Services - Pre Clinical Trials, Clinical Trials Stages 1-4, CRO, Clinical Data; Contract Services - Contract ServicesFormulation development
Sales markets Oceania; North America (USA, Canada); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from United Kingdom; United States

More products from QUOTIENT SCIENCES LIMITED

View all our products (17)
Orphan Drug Development

Contact information

Address

Telephone

Website

View all contact information
Curia - From Curiosity to Cure

Curia - From Curiosity to Cure

Datwyler Pharma Packaging

Datwyler Pharma Packaging

Alfasigma  Contract Manufacturing Showroom

Alfasigma Contract Manufacturing Showroom

CONTENT GROUP

CONTENT GROUP

Lonza

Lonza